Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedAug 31, 2026
DataAggregated Company Financials
Companies47
  • 7D2.5%
  • 3M3.4%
  • 1Y20.6%
  • YTD18.6%

In the last week, the Biotech industry is up 2.5%, with Vitrolife up 3.9%. In the last 12 months, the industry was up 21%. Earnings are forecast to grow by 35% annually.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 01 Sep 2026SEK 250.8bSEK 39.7b-SEK 5,882,406,771.8033.6x-42.6x6.3x
Thu, 30 Jul 2026SEK 252.6bSEK 40.1b-SEK 5,601,046,361.1633.6x-45.1x6.3x
Sat, 27 Jun 2026SEK 249.0bSEK 38.4b-SEK 5,989,946,819.9836.2x-41.6x6.5x
Mon, 25 May 2026SEK 250.4bSEK 38.4b-SEK 6,036,311,745.5424.5x-41.5x6.5x
Wed, 22 Apr 2026SEK 236.7bSEK 38.5b-SEK 5,607,539,593.9717.3x-42.2x6.2x
Fri, 20 Mar 2026SEK 210.1bSEK 38.5b-SEK 5,715,133,362.0016.7x-36.8x5.5x
Sun, 15 Feb 2026SEK 229.1bSEK 38.7b-SEK 5,474,857,079.7228.6x-41.8x5.9x
Tue, 13 Jan 2026SEK 209.6bSEK 38.1b-SEK 556,305,389.5736.2x-376.8x5.5x
Thu, 11 Dec 2025SEK 205.0bSEK 38.1b-SEK 603,633,587.6531.4x-339.6x5.4x
Sat, 08 Nov 2025SEK 199.5bSEK 37.3b-SEK 1,183,929,144.9937.1x-168.5x5.3x
Mon, 06 Oct 2025SEK 211.5bSEK 36.4bSEK 3.0b32.2x69.9x5.8x
Wed, 03 Sep 2025SEK 197.2bSEK 36.4bSEK 3.1b31.5x64.6x5.4x
Fri, 01 Aug 2025SEK 188.1bSEK 35.9bSEK 2.8b28x67.4x5.2x
Sun, 29 Jun 2025SEK 185.5bSEK 35.2bSEK 2.2b29.4x83.4x5.3x
Tue, 27 May 2025SEK 188.1bSEK 35.2bSEK 2.2b29.9x86.3x5.3x
Thu, 24 Apr 2025SEK 183.7bSEK 33.7bSEK 757.9m29.3x242.4x5.5x
Sat, 22 Mar 2025SEK 193.8bSEK 33.7bSEK 723.4m33.1x267.9x5.8x
Mon, 17 Feb 2025SEK 207.7bSEK 33.3bSEK 346.3m45.7x599.9x6.2x
Wed, 15 Jan 2025SEK 216.0bSEK 33.0b-SEK 4,402,338,767.02150.8x-49.1x6.5x
Fri, 13 Dec 2024SEK 212.1bSEK 33.0b-SEK 4,445,656,495.28141.9x-47.7x6.4x
Sun, 10 Nov 2024SEK 214.4bSEK 33.2b-SEK 4,187,800,234.70146.7x-51.2x6.5x
Tue, 08 Oct 2024SEK 207.6bSEK 31.4b-SEK 5,523,799,556.3848.8x-37.6x6.6x
Thu, 05 Sep 2024SEK 212.5bSEK 31.5b-SEK 5,518,282,956.0249.4x-38.5x6.8x
Sat, 03 Aug 2024SEK 194.1bSEK 31.4b-SEK 5,420,171,537.8743.2x-35.8x6.2x
Mon, 01 Jul 2024SEK 196.6bSEK 30.6b-SEK 5,537,729,202.1039.3x-35.5x6.4x
Wed, 29 May 2024SEK 191.1bSEK 30.6b-SEK 5,400,007,476.4439.1x-35.4x6.2x
Fri, 26 Apr 2024SEK 182.4bSEK 30.8b-SEK 5,554,927,800.4354.1x-32.8x5.9x
Sun, 24 Mar 2024SEK 184.6bSEK 29.8b-SEK 5,636,766,957.1158.7x-32.8x6.2x
Tue, 20 Feb 2024SEK 179.6bSEK 29.7b-SEK 5,699,202,242.0650.5x-31.5x6x
Thu, 18 Jan 2024SEK 186.9bSEK 28.7b-SEK 1,200,066,697.0059x-155.7x6.5x
Sat, 16 Dec 2023SEK 196.9bSEK 28.7b-SEK 1,170,293,890.0060.4x-168.2x6.9x
Mon, 13 Nov 2023SEK 160.8bSEK 28.7b-SEK 1,239,683,686.0050.6x-129.7x5.6x
Wed, 11 Oct 2023SEK 158.8bSEK 27.4b-SEK 2,015,877,318.0049x-78.8x5.8x
Fri, 08 Sep 2023SEK 151.3bSEK 27.4b-SEK 1,977,647,867.0047.9x-76.5x5.5x
Price to Earnings Ratio

-76.5x


Total Market Cap: SEK 151.3bTotal Earnings: -SEK 1,977,647,867.00Total Revenue: SEK 27.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -37.9x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 13% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market1.35%
Healthcare1.81%
Biotech2.53%
Biotech2.53%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VITR VitrolifeSEK 94.853.9%
+SEK 480.8m		-31.6%PS3.8x
EGTX Egetis TherapeuticsSEK 7.854.5%
+SEK 158.1m		50.7%PS55.3x
HNSA Hansa BiopharmaSEK 43.203.3%
+SEK 138.4m		29.9%PS23.2x
MVIR MedivirSEK 1.959.5%
+SEK 105.0m		0.3%PS138.7x
ONCO OncopeptidesSEK 1.9116.1%
+SEK 104.8m		-63.0%PS7.9x

Latest News

BIOA B
SEK 318.40
BioArctic
7D
-3.5%
1Y
3.0%
Analysis Article • Aug 30

BioArctic AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

As you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of kr248m beat...
CURAS
DKK 11.75
Curasight
7D
-25.9%
1Y
146.3%
Analysis Article • Aug 29

We're Keeping An Eye On Curasight's (NGM:CURAS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, Curasight...
CRNO B
SEK 4.36
Cereno Scientific
7D
-5.3%
1Y
-55.1%
ONCO
SEK 1.91
Oncopeptides
7D
16.1%
1Y
-63.0%
BINV
SEK 22.75
BioInvent International
7D
-6.4%
1Y
-27.1%
MVIR
SEK 1.95
Medivir
7D
9.5%
1Y
0.3%
FLUO
SEK 34.10
FluoGuide
7D
9.6%
1Y
-16.0%
SYNACT
SEK 20.00
SynAct Pharma
7D
5.3%
1Y
9.6%
VICO
SEK 10.32
Vicore Pharma Holding
7D
-2.6%
1Y
-9.8%
EGTX
SEK 7.85
Egetis Therapeutics
7D
4.5%
1Y
50.7%
SOBI
SEK 449.80
Swedish Orphan Biovitrum
7D
-0.5%
1Y
58.9%
Narrative Update • Aug 18

SOBI: Execution Risks Will Test Confidence In Elevated Margin Assumptions

The analyst price target for Swedish Orphan Biovitrum has been raised from SEK 315.00 to SEK 375.50. Analysts point to higher assumed revenue growth and profit margins, refreshed Street targets in the SEK 475 to SEK 575 range, and updated P/E expectations as key drivers of the revision.
VITR
SEK 94.85
Vitrolife
7D
3.9%
1Y
-31.6%
Narrative Update • Aug 12

VITR: CEO Transition And Higher Margin Outlook Will Support Future Upside

Analysts have reset their price target for Vitrolife from SEK 215 to SEK 155. They adjusted assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple in their updated models.
HNSA
SEK 43.20
Hansa Biopharma
7D
3.3%
1Y
29.9%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
BIOG B
SEK 114.70
BioGaia
7D
-1.4%
1Y
8.8%
Narrative Update • Jul 21

BIOG B: Dividend Power And Skincare Expansion Will Support Future Rerating

Analysts have trimmed their price target on BioGaia to SEK 152.50 from SEK 165.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News BioGaia New Sciences AB expanded the BioGaia Skincare portfolio with two new products, Gentle Balm to Milk Wash and Soothing Face & Body Lotion, and introduced an updated design across the full range, targeting babies and children with dry, sensitive and atopic prone skin.
BONEX
SEK 218.60
Bonesupport Holding
7D
-0.3%
1Y
-31.1%
Narrative Update • Jul 20

BONEX: Share Buybacks Will Support Bullish Case Despite Lowered Growth Assumptions

Analysts have reduced their price target for Bonesupport Holding to SEK275 from SEK310, reflecting updated assumptions around a slightly higher discount rate, more moderate revenue growth, a marginally stronger profit margin, and a lower future P/E multiple. What's in the News for Bonesupport Holding Bonesupport Holding AB (publ) plans to commence a share repurchase program on June 9, 2026, following a mandate from the Annual General Meeting on May 12, 2026.